KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Accounts Payables (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Accounts Payables readings, the most recent being $65.1 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 25.98% to $65.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $65.1 million, a 25.98% increase, with the full-year FY2025 number at $65.1 million, up 25.98% from a year prior.
  • Accounts Payables hit $65.1 million in Q4 2025 for Esperion Therapeutics, down from $77.5 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $77.5 million in Q3 2025 to a low of $12.8 million in Q2 2022.
  • Median Accounts Payables over the past 5 years was $28.9 million (2021), compared with a mean of $36.5 million.
  • Biggest five-year swings in Accounts Payables: tumbled 66.22% in 2021 and later soared 153.21% in 2025.
  • Esperion Therapeutics' Accounts Payables stood at $17.6 million in 2021, then surged by 31.21% to $23.0 million in 2022, then surged by 37.66% to $31.7 million in 2023, then surged by 62.84% to $51.6 million in 2024, then increased by 25.98% to $65.1 million in 2025.
  • The last three reported values for Accounts Payables were $65.1 million (Q4 2025), $77.5 million (Q3 2025), and $74.7 million (Q2 2025) per Business Quant data.